Lilly to buy ocular gene therapy maker Adverum in its fourth acquisition of the year
礼来将收购眼科基因疗法开发商 Adverum Biotechnologies，年内第四笔收购

With its fourth biotech acquisition of the year, Eli Lilly is further bolstering its gene therapy portfolio as other large drugmakers reassess their work in the complex, commercially-strained field.
礼来在今年完成第四桩生物技术收购之际，继续强化其基因疗法管线；与此同时，其他大型药企正重新审视这一复杂且商业承压的领域。